Biocryst Pharmaceuticals (BCRX) Other Non Operating Income (2011 - 2026)

Biocryst Pharmaceuticals has reported Other Non Operating Income for 16 years, with the latest figure at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income changed N/A year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 462.5% YoY), and the FY2025 full-year result was -$152000.0, up 76.29% from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$1.5 million, down from $6.8 million in the prior quarter.
• The five-year high for Other Non Operating Income was $6.8 million in Q4 2025, with the low at -$29.0 million in Q2 2023.
• Historically, Other Non Operating Income has averaged -$2.4 million across 5 years, with a median of -$383500.0 in 2022.
• Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 510.34% — and 2025, when it jumped 1219.04%.
• Biocryst Pharmaceuticals' Other Non Operating Income stood at -$538000.0 in 2022, then plunged by 36.99% to -$737000.0 in 2023, then gained by 18.05% to -$604000.0 in 2024, then surged by 1219.04% to $6.8 million in 2025, then slumped by 121.63% to -$1.5 million in 2026.
• The last three Other Non Operating Income figures came in at -$1.5 million (Q1 2026), $6.8 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.